At Asphalion, we are excited to kick off the #SINPAIN project in Spain today, where we are proud Regulatory partners!
Osteoarthritis is the most common joint disorder worldwide, but there is no efficient treatment so far. Over the next 4,5 years, #SINPAIN team strives to develop an efficient therapy to improve the quality of life for those affected and reduce the high costs associated with this condition.
The objective is to create a siRNA-combined advanced therapy, which will lead to more personalised treatment options for different stages of osteoarthritis.
Have a look at the project website to discover more insights:
For further information, you can also contact us at: email@example.com